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SPECIAL ARTICLE
INTRODUCTION
Stress ulcer‑related gastrointestinal bleeding is a potential complication of 
critical illness, for which the pathophysiology is complex. Systemic hemodynamic 
and local alterations result in gastric mucosal blood flow impairment with 
subsequent ischemic mucosal injury. However, the crucial factor for the 
development of ulceration and gastric bleeding is the high gastric intraluminal 
acidity, which is potentiated by fasting.(1) This provides the rationale for the use 
of acid‑suppressive drugs for pharmacological prophylaxis.(2)
Endoscopically evident upper gastrointestinal lesions may be found in up 
to 90% of critically ill patients within 3 days of admission;(3) less than 50% of 
patients will have occult bleeding (defined as guaiac‑positive gastric aspirate or 
guaiac‑positive stool) and approximately 5%(4,5) will have overt bleeding (defined 
as hematemesis, bloody gastric aspirate, melena, or hematochezia). However, 
this does not necessarily translate into clinically significant gastrointestinal 
bleeding (defined as overt bleeding in the presence of hypotension, tachycardia 
or orthostasis, a drop in hemoglobin of > 2g/dL, or the need for surgery),(6) 
whose incidence seems to have decreased over the years. In studies published 
before 1999, the incidence of clinically significant gastrointestinal bleeding 
was between 2% and 6% in patients not receiving prophylaxis.(6) However, 
in studies published since 2001, the incidence has been reported to range 
between 0.1% and 4% with or without prophylaxis,(7) which is related to better 
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Critically ill patients are at risk 
of developing stress ulcers in the 
upper digestive tract. Agents that 
suppress gastric acid are commonly 
prescribed to reduce the incidence of 
clinically important stress ulcer‑related 
gastrointestinal bleeding. However, 
the indiscriminate use of stress ulcer 
prophylaxis in all patients admitted to 
the intensive care unit is not warranted 
and can have potential adverse clinical 
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overall critical care, including the increased use of early 
enteral feeding. This, along with concerns related to the 
reported increasing frequency of infectious complications 
(nosocomial pneumonia and Clostridium difficile 
infections),(8,9) has challenged the traditional cornerstone 
of pharmacological prophylaxis with agents that suppress 
gastric acid for stress ulcer prophylaxis.(10)
This guideline from the Sociedade Portuguesa de 
Cuidados Intensivos aims to summarize current evidence 
and give clinical recommendations for the use of stress 
ulcer prophylaxis in the intensive care unit (ICU) to 
provide a standardized prescribing policy and avoid 
injudicious use.
METHODOLOGY
A multidisciplinary task force was assembled. The task 
force comprised physicians (specialists in gastroenterology 
and intensive care medicine), nurses, pharmacists and 
economists with special interest and expertise in stress 
ulcer prophylaxis and/or evidence‑based medicine. All 
members of the task force declared that no conflict of 
interest influenced the development of the guidelines.
Task force members participated in a discussion via 
e‑mail, and six clinical questions were built for evidence 
evaluation. Each working member took charge of one 
clinical question and built search queries in the PICO 
(Participants, Interventions, Comparisons, and Outcomes) 
format.(11) The availability of a Cochrane review(12) relevant 
to the clinical questions was confirmed by searching the 
Cochrane Database of Systematic Reviews. A further 
complementary literature search of PubMed® was 
performed. Trial data identified by the search strategies 
were considered to represent the best‑quality evidence. The 
Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) system principles(13) was used 
to assess the quality of evidence from high to very low and 
to determine the strength of recommendations.
Finally, the task force determined the direction 
(for or against) and strength (strong or weak) of the 
recommendations using a two‑round (self‑administered 
questionnaire with no meetings among the participants) 
simple Delphi method.(14) This was done according 
to the GRADE system and considered the following 
factors: evidence quality, certainty in the balance between 
advantages and disadvantages, certainty or similarity in 
values and preferences, and resource implications. Arriving 
at a consensus required an average level of agreement of 
≥ 80%. When the agreement level was < 80%, further 
discussions and voting were conducted.
A strong recommendation was worded as “we 
recommend” and a weak recommendation as “we suggest”.
The key recommendations were presented at the 
annual symposium of the Sociedade Portuguesa de 
Cuidados Intensivos in Oporto and discussed by the panel 
and audience members.
STATEMENTS
Statement 1
We recommend maintaining (or initiating) agents 
that suppress gastric acid (namely, proton‑pump 
inhibitors) in patients with compelling indications for 
acid suppression. Strong recommendation, moderate 
quality of evidence.
Rational
Several clinical situations require gastric acid 
suppression (namely, proton‑pump inhibitors), and 
indications should be respected, both in the ambulatory 
and hospital (including intensive care) settings.
Patients with compelling indications include the 
following:
‑ Known peptic ulcer disease in the healing phase 
and maintenance phase in selected circumstances 
[> 50 years old; multiple comorbidities; persistent 
symptoms; NSAID‑negative and Helicobacter 
pylori‑negative ulcers; need to continue NSAID 
or failure to eradicate Helicobacter pylori; ulcers 
complicated at the outset; and giant (> 2cm), 
refractory or recurrent ulcers].(15)
‑ Treatment of Helicobacter pylori infection.(16)
‑ Zollinger‑Ellison syndrome and other 
hypersecretory conditions.(17)
‑ Gastroesophageal reflux disease and acid‑related 
complications (i.e., erosive esophagitis or peptic 
stricture)(18) and Barrett’s esophagus.(19)
‑ Eosinophilic esophagitis.(20)
‑ Dual antiplatelet therapy or concomitant 
anticoagulant therapy.(21)
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Other approved indications (which should be discussed 
on a case‑by‑case basis) include the following:
‑ Uninvestigated dyspepsia(22) and epigastric pain 
syndrome.(23)
Approved indications may vary with specific acid 
suppressants, and therefore labeling indications should be 
considered.
Statement 2
We recommend prophylaxis with agents that suppress 
gastric acid rather than no prophylaxis in patients who 
have one major risk factor or two minor risk factors for 
stress ulceration.
complications. This metanalysis has been criticized, and a 
number of large phase‑III trials comparing pharmacological 
prophylaxis and placebos are under way. Their results and 
subsequent updated meta‑analyses are expected to provide 
important, more relevant data on the balance between the 
benefits and harms of stress ulcer prophylaxis.(27)
Importantly, the incidence of stress ulcer‑related 
gastrointestinal bleeding is not equally shared across the 
spectrum of patients admitted to intensive care, and 
certain patients appear more at risk for bleeding.
A large multicenter prospective cohort study(4) identified 
coagulopathy (defined as a platelet count < 50,000/m3, an 
international normalized ratio greater than 1.5, or a partial 
thromboplastin time greater than 2 times the control value) 
and respiratory failure (defined as the need for mechanical 
ventilation for at least 48 hours) as major risk factors 
for clinically significant gastrointestinal bleeding. The 
robustness of these risk factors has been confirmed in at 
least one additional small observational study.(28)
Older studies have been criticized because clinical 
practice has undergone major changes(10) in the last 
20 years, which have reduced the incidence of stress 
ulcer‑related gastrointestinal bleeding. Moreover, in line 
with what was previously described, a recent exploratory 
randomized clinical trial(29) comparing pharmacologic 
prophylaxis (with proton‑pump inhibitors) and a 
placebo in mechanically ventilated critically ill patients 
anticipated to receive enteral nutrition did not show any 
benefit (or harm) of acid suppression. Because this was a 
feasibility trial, no firm evidence could be inferred, and 
the final conclusion was that it is possible to administer 
pharmacologic prophylaxis promptly after commencing 
mechanical ventilation.
Patients with traumatic brain injury (Glasgow 
Coma Scale score ≤ 8), traumatic spinal cord injury, 
or burn injury (> 35% of the body surface area) have 
been routinely excluded from these studies because of a 
presumed high‑risk of stress ulcer‑related gastrointestinal 
bleeding most likely mediated through neurological 
pathways.(30) Nevertheless, small randomized controlled 
trials(31‑33) with different acid suppression regimens 
have demonstrated significant protection from stress 
ulcer‑related gastrointestinal bleeding in these high‑risk 
populations.
Major risk factor:
- Coagulopathy (defined as a platelet count < 50,000/m3, an International 
Normalized Ratio (INR) greater than 1.5, or a partial thromboplastin time 
greater than 2 times the control value).
- Respiratory failure (defined as the need for mechanical ventilation for at least 
48 hours). 
- Traumatic brain injury (Glasgow Coma Scale score ≤8), traumatic spinal cord 
injury, or burn injury (>35% of the body surface area).
- Sepsis (acute change in total Sequential Organ Failure Assessment - SOFA 
score ≥ 2 points consequent to infection).
Minor risk factors:
- Acute or chronic renal failure (needing intermittent or continuous renal 
replacement therapy).
- Shock (defined as continuous infusion with vasopressors or inotropes, mean 
arterial blood pressure below 70mmHg or plasma lactate level equal to or 
greater than 4mmol/L).
- Chronic hepatic failure (defined as cirrhosis proven by biopsy, history of 
variceal bleeding or hepatic encephalopathy).
- Glucocorticoid therapy (≥ 250mg hydrocortisone equivalent per day).
- Multiple trauma with an injury severity score ≥ 16.
Strong recommendation, low quality of evidence.
Rational
Meta‑analysis and systematic reviews(6,24,25) have 
consistently shown that agents that suppress gastric acid 
(namely, histamine‑2‑receptor antagonists and/or proton‑
pump inhibitors) are superior to placebos in reducing 
the risk of clinically significant gastrointestinal bleeding. 
However, a recent meta‑analysis(26) suggested that 
in patients receiving enteral feeding, pharmacologic 
prophylaxis of stress ulcers is not beneficial, and combined 
interventions may even increase the risk of some infectious 
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No study has been performed specifically for sepsis; 
however, stress ulcer prophylaxis has been an integral 
part of the care of septic patients and is recommended 
by current guidelines.(34) This makes sense regarding the 
new sepsis definitions(35) in which the infection‑related 
dysregulated host response has to be associated with a 
severe (life‑threatening) organ dysfunction (identified as 
an acute change in total SOFA score ≥ 2 points), and thus 
includes multiple risk factors.
The evidence supporting other minor risk factors for 
stress ulcer‑related gastrointestinal bleeding is weak as 
a result of a high risk of systematic and random errors. 
However, an increasing number of risk factors is associated 
with an increased risk of bleeding,(36) and international 
guidelines recommended stress ulcer prophylaxis for 
patients with two or more risk factors.(37) In the original 
description of stress‑ulcer bleeding, hypotension 
(alongside sepsis and respiratory failure) was associated 
with stress‑related mucosal damage.(38) A recent inception 
cohort study identified the presence of three or more 
comorbidities (including glucocorticoid therapy), 
preexisting liver disease, renal failure (with use of renal 
replacement therapy), and coexisting or acute coagulopathy 
and higher SOFA‑score, as significant risk factors for 
stress‑ulcer bleeding after multivariate analysis.(39) In 
another large cohort study,(40) acute kidney injury (assessed 
by maximum serum creatinine level) was independently 
associated with an increased risk of gastrointestinal 
bleeding in patients mechanically ventilated for more than 
48 hours. Additionally, a small prospective randomized 
trial(33) demonstrated independent significance for the 
injury severity score.
Statement 3
We recommend the use of a proton‑pump inhibitor 
when prophylaxis with agents that suppress gastric acid 
is indicated. Strong recommendation, low quality of 
evidence.
Rational
The choice of the pharmacological prophylaxis agent 
should take into account factors related to effectiveness, 
adverse effects and cost.
Sucralfate, a mucosa‑protective agent, alone has 
traditionally been considered inferior to histamine‑
2‑receptor antagonists for stress ulcer prophylaxis.(6,41) 
While this has been challenged in a recent meta‑analysis 
of randomized controlled trials,(42) the results have been 
criticized because of significant heterogeneity between 
studies, of which only three had clinically significant 
gastrointestinal bleeding as a reported outcome.(43)
The efficacy of proton‑pump inhibitors and histamine‑
2‑receptor antagonists in preventing stress‑ulcer bleeding 
in critically ill patients has been compared in several 
randomized control trials and meta‑analyses.(25,44‑48) The 
most recent and complete meta‑analyses of randomized 
controlled trials(25,44) consistently demonstrated that 
proton‑pump inhibitors were more effective than 
histamine‑2‑receptor antagonists at reducing clinically 
significant gastrointestinal bleeding, although this was not 
accompanied by a reduction in ICU mortality or length of 
stay. The robustness of these conclusions is limited by the 
trial methodologies, differences between lower and higher 
quality trials, sparse data and possible publication bias. An 
ongoing cluster‑randomized crossover trial [Australian and 
New Zealand Intensive Care Society Clinical Trials Group 
(ANZICS CTG): study number 1415‑01] is comparing 
proton‑pump inhibitors and histamine‑2‑receptor 
antagonists, and the results are expected to provide more 
relevant data.(27)
There are multiple pharmacoeconomic analyses(49‑51) 
focused on the comparison between histamine‑2‑
receptor antagonists and proton pump inhibitors for the 
prophylaxis of stress ulcerrelated gastrointestinal bleeding. 
The results are contradictory, mainly due to the use of 
different clinical inputs, and there is no strong evidence 
regarding which is the most effective alternative. Data from 
the most recent meta‑analysis of clinical trials indicate 
that proton pump inhibitors should be used. However, 
if one relies on a propensity score‑matched observational 
cohort study, histamine‑2‑receptor antagonists are the 
preferred option.(51) The only clear conclusion is that, as 
the cost of prophylaxis is small when compared to the 
costs of complications, the most effective alternative will 
constitute a dominant alternative.(51)
Although the quality of evidence is suboptimal, 
proton‑pump inhibitors have been the preferred regimen 
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in intensive care units across Europe, the United States 
and Canada.(52,53) It is acknowledged that the published 
literature on this issue derives from heterogeneous 
populations of critically ill patients who may differ 
from the populations at risk identified by the previous 
recommendation.
Additionally, the expected adverse effects of proton‑
pump inhibitors are a concern and must be taken into 
account. A cohort study(54) provided evidence of an 
increase in pneumonia with proton‑pump inhibitor use; 
however, this study was related only to cardiac surgery 
patients, and confidence intervals were wide. Small 
randomized trials (29,55) and a case–control study showed an 
increased adjusted risk for Clostridium difficile infections 
during treatment with proton‑pump inhibitors, but this 
was more related to the duration of exposure.(56)
Ultimately, the desirable consequences of stress ulcer 
prophylaxis with proton‑pump inhibitors are expected 
to outweigh the undesirable consequences among the 
population at risk.
Statement 4
We make no recommendation regarding specific 
proton‑pump inhibitor regimens.
Rational
The ideal drug regimen should be effective in reducing 
the risk of ulceration, with a low potential for adverse 
effects and drug interactions and pharmacokinetic 
characteristics that facilitate its use in patients with organ 
dysfunction; it should also be cost‑effective.
There is no direct comparison between different 
proton‑pump inhibitor‑based regimens (including drug, 
dosing, route of administration and galenic formulation), 
and heterogeneity across studies (comparing proton‑pump 
inhibitors to other regimens) impairs the comparison of 
effects between the individual proton‑pump inhibitor 
regimens tested to date. An a priori defined subgroup 
analysis of at least one meta‑analysis suggests that the route 
of administration (enteral versus intravenous) and dosing 
(once versus twice a day) do not affect the results.(43,45)
In relation to the route of administration, multiple 
factors (e.g., vasopressor use, altered gastric emptying 
and motility, feeding tube and nutrient interactions) 
may influence enteral absorption in critically ill patients, 
and the intravenous route is generally preferred.(57) This 
is disputed by a study showing that, despite a lower 
bioavailability, enteral lansoprazole suppressed acid in 
intensive care unit patients better than the intravenous 
formulation.(58) However, this has not been confirmed 
by further studies, and lansoprazole requires a complex 
and labor‑intensive galenic formulation for feeding tube 
administration.
Due to its safety in (at least moderate) organ 
dysfunction, lower probability of drug‑drug interactions, 
and available formulations, intravenous pantoprazole 
(40mg qd) may be a reasonable choice.(59) However, the 
definitive choice of the specific proton‑pump inhibitor 
regimen should be based on individual patient and 
medical values, experience, product labeling, cost‑benefit 
analyses, anticipated risks of drug‑drug interactions and 
adverse effects.
Statement 5
We suggest using histamine‑2‑receptor antagonists in 
patients with Clostridium difficile infection and indications 
for stress ulcer prophylaxis. Weak recommendation, very 
low quality of evidence.
Rational
Accumulating evidence suggests that the use of agents 
that suppress gastric acid may increase the frequency 
of infectious complications.(8,9,60) The most recent and 
comprehensive meta‑analysis(61) found that therapy with 
agents that suppress gastric acid was associated with a 
significant risk of Clostridium difficile infections but that 
the risk was lower for histamine‑2‑receptor antagonists 
than with proton‑pump inhibitors.
In the critically ill population, the increased risk for 
Clostridium difficile infections is still controversial because 
meta‑analysis is weak in detecting a modest increase in 
these events.(62) Nevertheless, the risk of Clostridium 
difficile infections remains higher in patients receiving 
proton‑pump inhibitors compared with patients 
receiving histamine‑2‑receptor antagonists.(8) Moreover, 
observational studies(63,64) have shown that continued 
proton‑pump inhibitor use during incident Clostridium 
difficile infections increases the risk of recurrence.
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Based on available data and given the significant 
disease burden and mortality associated with Clostridium 
difficile infections, proton‑pump inhibitors should be 
avoided, and histamine‑2‑receptor antagonists should 
be the preferred therapy when stress ulcer prophylaxis is 
indicated.(62)
Statement 6
We recommend stopping prophylaxis with agents 
that suppress gastric acid when risk factors are no longer 
present and the patient is receiving enteral nutrition. 
Strong recommendation, low quality of evidence.
Rational
Acid suppressants are inappropriately continued 
in a large proportion of patients after the resolution of 
risk factors and even after intensive care unit or hospital 
discharge, thus extending the potential risks and costs 
associated with stress ulcer prophylaxis beyond the 
intensive care unit.(65) This is in agreement with studies 
that have concluded that 88.5% of stress ulcer prophylaxis 
in nonintensive care unit patients is inappropriate(66) and 
that a relatively restrictive stress ulcer prophylaxis program 
not only reduces inappropriate use without increasing the 
rates of hospital‑related gastrointestinal bleeding but also 
results in an estimated annualized cost savings of more 
than US$ 200.000.(67)
As previously described,(26) there is some evidence 
to suggest that in patients receiving enteral feeding, 
pharmacologic stress ulcer prophylaxis is not beneficial, 
and combined interventions may even increase the 
risk of some infectious complications. However, the 
evidence is still insufficient to justify withholding stress 
ulcer prophylaxis from patients who are at high risk for 
gastrointestinal bleeding. It is sufficiently compelling to 
support the cessation of prophylaxis when risk factors 
are no longer present and the patient is receiving enteral 
nutrition.
Patients should thus be evaluated daily during 
multidisciplinary care rounds for the continued need 
for prophylaxis, and once the patient is receiving enteral 
nutrition and risk factors are no longer present, stress 
ulcer prophylaxis should be discontinued. This strategy 
will reduce the overuse and unnecessary continuation of 
agents that suppress gastric acid upon discharge and in 
the outpatient setting.(68) As one of the more common 
indications for stress ulcer prophylaxis is mechanical 
ventilation, extubation is crucial to identify and possibly 
discontinue acid suppression therapy.(62)
General algorithm
The general algorithm for the prophylaxis of stress ulcer 
bleeding in the intensive care unit is presented in figure 1. 
Patients with compelling indications for acid suppression 
should have an acid‑suppressive regimen in accordance 
with the indication (Statement 1). Then, the risk for 
bleeding should be considered in each patient; the use of 
stress ulcer prophylaxis is appropriate for those with high 
risk. Patients at low risk should not start (or discontinue 
if previously initiated) stress ulcer prophylaxis (Statement 
2). When a stress ulcer prophylaxis is recommended, the 
use of a proton‑pump inhibitor is indicated (Statement 
3) with no specific recommended regimen (Statement 4). 
The exception is cases of Clostridium difficile infection, 
for which histamine‑2‑receptor antagonists are preferred 
(Statement 5). Once the patient is receiving enteral 
nutrition and risk factors are no longer present, stress 
ulcer prophylaxis should be discontinued (Statement 6). 
Table 1 compares the different available proton‑pump 
inhibitor‑ and histamine‑2‑receptor antagonist‑based 
regimens.
The authors suggest that the practices recommended in 
this guideline are continuously evaluated and monitored 
and that this guideline is updated as new evidence becomes 
available.
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Figure 1 - Algorithm  for prophylaxis of stress ulcer bleeding in the intensive care unit. * If Clostridium difficile infection and indications for stress ulcer prophylaxis favor histamine-
2-receptor antagonists. INR - International Normalized Ratio; aPPT - activated partial thromboplastin time; SOFA - Sequential Organ Failure Assessment.
Table 1 - Comparison of the different available proton-pump inhibitor- and histamine-2-receptor antagonist-based regimens
Drug
Pharmaceutical 
formulation
Dosing
Dosing and route of 
administration
Reconstitution and administration Dose adjustment
Relevant major 
pharmacological 
interactions (grade 
1 - 2 impact)
Pantoprazole Powder for injection 
solution
40mg qd Intravenous Reconstitute 40mg with 10cc of 0.9% 
NaCl and administer for 2 minutes (if 
necessary dilute in 100cc of 0.9% NaCl 
or 5% dextrose in H2O)
Hepatic failure 
(moderate to severe)
Azoles*
Reverse protease 
inhibitors†
Gastroresistant tablet Oral* –
Omeprazole Powder for injection 
solution
40mg qd Intravenous Reconstitute 40mg with 5cc of 0.9% 
NaCl and administer for 20 - 30 minutes 
(if necessary dilute in 100cc of 0.9% 
NaCl or 5% dextrose in H2O)
Hepatic failure 
(moderate to severe)
Azoles†
Reverse protease 
inhibitors†
Clopidogrel‡
Gastroresistant 
capsule
Oral –
Endogastric or 
endojejunal feeding 
tube
Open capsules, disperse the content in 
40mL of non-carbonated water, shake 
vigorously and allow to stand for 2 
minutes (until thick)
Continue...
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* No data on enteral administration; consider alternative drugs; † consider alternative drugs; ‡ consider substitution by pantoprazole. NaCl - sodium chroride.
Drug
Pharmaceutical 
formulation
Dosing
Dosing and route of 
administration
Reconstitution and administration Dose adjustment
Relevant major 
pharmacological 
interactions (grade 
1 - 2 impact)
Lansoprozole Gastroresistant 
capsule
30mg qd Oral – Hepatic failure 
(moderate to severe)
Azoles†
Reverse protease 
inhibitors†
Endogastric or 
endojejunal feeding 
tube
Open capsules and disperse the content 
in 40mL of (orange or apple) juice
Orodispersible tablet Oral –
Endogastric or 
endojejunal feeding 
tube
Disperse in 10mL of non-carbonated 
water
Esomeprazole 
40mg i.v. qd
Powder for injection 
solution
40mg qd Intravenous Hepatic failure 
(moderate to severe)
Azoles†
Reverse protease 
inhibitors†
Clopidogrel‡
Gastroresistant 
capsule
Oral –
Endogastric or 
endojejunal feeding 
tube
Open capsules, disperse the granules in 
40mL of non-carbonated water
Gastroresistant tablet Oral –
Ranitidine Powder for injection 
solution
50mg tid Intravenous Reconstitute 50mg with 20cc of 0.9% 
NaCl and administer for 5 minutes
Continuous perfusion: after a 50mg bolus 
(see above), dilute 150mg to 250cc 
of 0.9% NaCl or 5% dextrose in H2O in 
perfusion at 10.4cc/hour 
Renal failure (clearance 
< 50mL/min/m2)
Azoles†
Coated tablet 150mg qd Oral –
Endogastric or 
endojejunal feeding 
tube
Grind tablets and reduce to powder, 
and disperse the content in 40mL of 
non-carbonated water
... continuation
O paciente crítico corre risco de desenvolver úlceras de 
estresse do trato gastrintestinal. Antiácidos e antiulcerosos de 
diferentes classes são frequentemente prescritos para reduzir a 
incidência de hemorragia gastrintestinal clinicamente significa‑
tiva associada à úlcera de estresse. No entanto, o uso indiscrimi‑
nado deste tipo de profilaxia em todos os pacientes admitidos a 
unidades de terapia intensiva não só não se justifica, como tem 
potenciais efeitos adversos e implicações de custo. As presentes 
diretrizes da Sociedade Portuguesa de Cuidados Intensivos re‑
sume a evidência atual e fornece seis afirmações clínicas e um 
algoritmo com o objetivo de fornecer uma política padronizada 
para prescrição de profilaxia da úlcera estresse em unidades de 
terapia intensiva.
RESUMO
Descritores: Estresse psicológico; Úlcera péptica; Profilaxia; 
Unidades de terapia intensiva
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